Clinical Study

Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer

Figure 1

Kaplan-Meier analysis of progression-free survival (N=44).
785934.fig.001